Display options
Cite
Hartman JC, Del Rio CL, Reardon JE, et al. Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure. JACC Basic Transl Sci. 2018;3(5):625-638doi: 10.1016/j.jacbts.2018.07.003.
Hartman, J. C., Del Rio, C. L., Reardon, J. E., Zhang, K., & Sabbah, H. N. (2018). Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure. JACC. Basic to translational science, 3(5), 625-638. https://doi.org/10.1016/j.jacbts.2018.07.003
Hartman, J Craig, et al. "Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure." JACC. Basic to translational science vol. 3,5 (2018): 625-638. doi: https://doi.org/10.1016/j.jacbts.2018.07.003
Hartman JC, Del Rio CL, Reardon JE, Zhang K, Sabbah HN. Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure. JACC Basic Transl Sci. 2018 Nov 12;3(5):625-638. doi: 10.1016/j.jacbts.2018.07.003. eCollection 2018 Oct. PMID: 30456334; PMCID: PMC6234500.
Copy Download .nbib Format: NLM
Share it on

JACC Basic Transl Sci. 2018 Nov 12;3(5):625-638. doi: 10.1016/j.jacbts.2018.07.003. eCollection 2018 Oct.

Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure.

JACC. Basic to translational science

J Craig Hartman, Carlos L Del Rio, John E Reardon, Kefei Zhang, Hani N Sabbah

Affiliations

  1. Pharmaceutical R&D Consulting, LLC, Loveland, Colorado.
  2. QTest Labs, LLC, Columbus, Ohio.
  3. Revivo Therapeutics, Inc., Durham, North Carolina.
  4. Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan.

PMID: 30456334 PMCID: PMC6234500 DOI: 10.1016/j.jacbts.2018.07.003

Abstract

The effects of the nitroxyl donor BMS-986231 on hemodynamics, left ventricular (LV) function, and pro-arrhythmic potential were assessed using canine heart failure models. BMS-986231 significantly (p < 0.05) increased LV end-systolic elastance, pre-load-recruitable stroke work, ejection fraction, stroke volume, cardiac output, ratio of early-to-late filling time integrals, and early mitral valve inflow velocity deceleration time. BMS-986231 significantly decreased LV filling pressures, end-diastolic stiffness, the time-constant of relaxation, end-diastolic wall stress, systemic vascular resistance, and myocardial oxygen consumption. BMS-986231 had little effect on heart rate and did not induce de novo arrhythmias. Thus, BMS-986231 has beneficial inotropic, lusitropic, and vasodilatory effects.

Keywords: DT, deceleration time of early mitral inflow velocity; EDPVR, end-diastolic pressure–volume relationship; ESPVR, end-systolic pressure–volume relationship; Ei/Ai, the ratio of early-to-late filling time integrals; HEX, Hextend (plasma volume-expanding solution); LVEDWS, left ventricular end-diastolic circumferential wall stress; LVEF, left ventricular ejection fraction; LVFAS, left ventricular fractional area shortening; MHC, myosin heavy chain; MLC1, myosin light chain 1; PRSW, pre-load-recruitable stroke work; RyR2, ryanodine receptor 2; SH, thiol group; SV, stroke volume; SVR, systemic vascular resistance; Tau, left ventricular relaxation time-constant; canine; cardiomyopathies; heart failure; hemodynamics; nitroxyl

References

  1. Front Physiol. 2017 Nov 10;8:894 - PubMed
  2. Antioxid Redox Signal. 2013 Oct 10;19(11):1185-97 - PubMed
  3. Circulation. 2012 Jul 24;126(4):501-6 - PubMed
  4. Eur J Heart Fail. 2017 Oct;19(10):1321-1332 - PubMed
  5. Am J Physiol. 1991 Apr;260(4 Pt 2):H1379-84 - PubMed
  6. J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133 - PubMed
  7. Cardiovasc Drugs Ther. 1993 Jun;7(3):349-56 - PubMed
  8. Eur J Heart Fail. 2016 Aug;18(8):891-975 - PubMed
  9. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10463-8 - PubMed
  10. Circulation. 2000 Mar 7;101(9):1040-8 - PubMed
  11. Antioxid Redox Signal. 2011 May 1;14(9):1659-74 - PubMed
  12. Circ Res. 2009 Mar 27;104(6):720-3 - PubMed
  13. Eur Heart J. 1992 Nov;13(11):1562-72 - PubMed
  14. Biochemistry. 2008 Dec 16;47(50):13150-2 - PubMed
  15. Front Biosci (Elite Ed). 2010 Jan 01;2:614-26 - PubMed
  16. Circ J. 2012;76(3):532-43 - PubMed
  17. Am Fam Physician. 2017 Jan 1;95(1):13-20 - PubMed
  18. Circ Heart Fail. 2013 Nov;6(6):1250-8 - PubMed
  19. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239 - PubMed
  20. Circ Res. 2007 Jan 5;100(1):96-104 - PubMed
  21. Curr Heart Fail Rep. 2014 Sep;11(3):227-35 - PubMed
  22. Circ Res. 2002 Aug 23;91(4):278-80 - PubMed
  23. Arterioscler Thromb Vasc Biol. 2005 May;25(5):915-22 - PubMed
  24. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5537-42 - PubMed
  25. Biochim Biophys Acta. 2009 Jul;1787(7):835-40 - PubMed
  26. ESC Heart Fail. 2014 Sep;1(1):4-25 - PubMed
  27. J Pharmacol Exp Ther. 2011 Dec;339(3):825-31 - PubMed

Publication Types